SLAM
SUPN icon

Swiss Life Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Swiss Life Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,077
Closed -$302K – 1611
2025
Q4 		$302K Buy
+6,077
New +$295K ﹤0.01% 1020

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Swiss Life Asset Management's SUPN Position: Q1 2026 in Review

Swiss Life Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 6,077 shares — an estimated $302K sold.

Swiss Life Asset Management first reported a position in SUPN in Q4 2025 and held it in 1 quarter. The position peaked at $302K in Q4 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Swiss Life Asset Management reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Swiss Life Asset Management sold 6,077 Supernus Pharmaceuticals shares in Q1 2026, an estimated $302K.
  • Swiss Life Asset Management first reported a position in Supernus Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Swiss Life Asset Management's Supernus Pharmaceuticals position peaked at $302K in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Swiss Life Asset Management's 13F filing for Q1 2026, filed 14 May 2026.